You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
金河生物(002688.SZ)上半年淨利潤9,500.54萬元 同比下降9.55%
格隆匯 08-23 16:25

格隆匯8月23日丨金河生物(002688.SZ)公佈,2020年半年度,公司公司實現營業收入8.48億元,比上年同期增加1.77%;實現營業利潤1.23億元,同比下降6.04%;歸屬於上市公司股東的淨利潤為9,500.54萬元,同比下降9.55%;歸屬於上市公司股東的扣除非經常性損益的淨利潤9191萬元,同比減少7.56%;每股收益0.15元。

藥物飼料添加劑業務:面對新冠疫情和國內獸藥監管政策變化的疊加影響,雖然公司採取了一系列積極應對措施,但自二季度開始國內外市場銷量均出現不同程度的下滑。報告期內,藥物飼料添加劑業務實現銷售收入4.37億元,比上年同期減少6,860.72萬元,減幅13.57%。

獸用疫苗業務:獸用疫苗業務經過近幾年的資源整合、技術提升,市場拓展初見成效。豬藍耳、豬圓環疫苗市場銷售向好。報告期內,獸用疫苗實現銷售收入8,887.96萬元,比上年同期增加5,374.46萬元,增幅152.97%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account